HERZOG C, DURRER P, SPYR C, LANG A, GLUCK U, GLUCK R; Interscience Conference on Antimicrobial Agents and Chemotherapy (41st : 2001 : Chicago, Ill.).

Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2001 Dec 16-19; 41: abstract no. G-446.

Swiss Serum and Vaccine Institute, Berne, Switzerland

Objectives: To compare the humoral immune responses of Escherichia coli heat-labile toxin (HLT) adjuvanted intranasal (i.n.) with intramuscular (i.m.) inactivated, virosome-formulated influenza vaccine in young and elderly adults, and to assess in young adults the antibody secreting cell (ASC) and mucosal immune responses. METHODS: Groups of 130 young (18-60y [Groups A, C]) and 110 elderly (>60y [Gr. B, D]) adults received i.n. on Days 1 and 8 spray doses of 200micro-l containing >/=7.5mg haemagglutinin (HA) from each of the 2000/01 WHO recommended influenza strains adjuvanted with 2mg HLT (Gr.A: n=58, 38.2y; Gr.B: n=56, 86.5y) or on Day 1 a single i.m. dose ([3]15mg HA per strain) of influenza vaccine (Gr.C: n=72, 35.2y; Gr.D: n=54, 69.5y). Tolerability was assessed for 4 weeks. Haemagglutination inhibition (HI) antibody titers were measured in serum on Days 1 and 21 (Gr. C, D)/29 (Gr. A, B). In Groups A (n=12) and C (n=14) anti-HA IgA was measured (ELISA) in nasal fluid on Days 1 and 21/29, as well as anti-HA IgA in saliva and ASC in full blood on Days 1, 7, 9, 11, 15, 22 and 29. RESULTS: For both vaccines and in both age groups the European (EMEA, London) age-specific HI immunogenicity criteria for i.m. influenza vaccines were fulfilled. Both vaccines showed strong IgA- and IgG-ASC responses, peaking on Day 7 for the i.m. and on Days 9/15 for the i.n. vaccine. No consistent IgA responses were found in saliva. In nasal fluid a sustained anti-HA IgA response was found with the i.n. (2.1-4.0-fold GMT rise), but not with the i.m. vaccine (1.0-1.2). Both vaccines were found to be safe. CONCLUSIONS: The HLT-adjuvanted i.n. influenza vaccine was found to be safe and highly immunogenic, eliciting at the nasal mucosa level a significant influenza-specific immune response not found with the i.m. vaccine.

Publication Types:

• Meeting Abstracts

Keywords:

• Adult
• Aged
• Bacterial Toxins
• Enterotoxins
• Enzyme-Linked Immunosorbent Assay
• Escherichia coli Proteins
• Hemagglutination Inhibition Tests
• Humans
• Influenza Vaccines
• London
• Vaccines
• Vaccines, Inactivated
• Virosomes
• enterotoxin LT

Other ID:

• GWAIDS0031032

UI: 102270669

From Meeting Abstracts